Stay updated on Fianlimab Combo vs Pembrolizumab in Melanoma Clinical Trial
Sign up to get notified when there's something new on the Fianlimab Combo vs Pembrolizumab in Melanoma Clinical Trial page.

Latest updates to the Fianlimab Combo vs Pembrolizumab in Melanoma Clinical Trial page
- Check3 days agoChange DetectedThe page’s displayed software/version label has been updated from **Revision: v3.5.2** to **Revision: v3.5.3**, indicating a site update rather than a change to the trial record itself.SummaryDifference0.1%

- Check10 days agoChange DetectedRevision v3.5.2 was added and revision v3.5.0 was removed from the study record history.SummaryDifference0.1%

- Check17 days agoNo Change Detected
- Check39 days agoChange DetectedAdded Revision: v3.5.0 and removed Revision: v3.4.3 in the Record History.SummaryDifference0.1%

- Check46 days agoChange DetectedA new revision entry v3.4.3 was added and v3.4.2 was removed from the history.SummaryDifference0.1%

- Check53 days agoChange DetectedNo additions or deletions were detected; the updates relate to study status and contacts/locations within the record.SummaryDifference0.1%

- Check74 days agoChange DetectedRevision updated from v3.4.1 to v3.4.2 in the page history. No study data or essential content was altered.SummaryDifference0.1%

Stay in the know with updates to Fianlimab Combo vs Pembrolizumab in Melanoma Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Fianlimab Combo vs Pembrolizumab in Melanoma Clinical Trial page.